Results 151 to 160 of about 6,484,256 (294)
Bird Types in the Carnegie Museum List of Types of Birds in the Collection of the Carnegie Museum, on May 1, 1928 W. E. Clyde Todd [PDF]
W. S.
openalex +1 more source
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau+11 more
wiley +1 more source
Development and recalibration of a multivariable type 1 diabetes prediction model for type 1 diabetes across multiple screening studies. [PDF]
Templeman EL+14 more
europepmc +1 more source
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti+10 more
wiley +1 more source
The pathophysiology, presentation and classification of Type 1 diabetes. [PDF]
Aamodt KI, Powers AC.
europepmc +1 more source
Dr. Joel Asaph Allen—An Appreciation<xref ref-type="fn" rid="fn1"><sup>1</sup></xref>
Edward William Nelson
openalex +2 more sources
Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson+11 more
wiley +1 more source
Type 1 diabetes in Brazil: a narrative overview of the Brazilian Type 1 Diabetes Study Group. [PDF]
Gomes MB+2 more
europepmc +1 more source
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu+11 more
wiley +1 more source
Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. [PDF]
Pulh P+9 more
europepmc +1 more source